Cargando…
T39. NEURAL MECHANISMS OF METABOTROPIC GLUTAMATE RECEPTOR 3 MEDIATED ENHANCEMENT OF SYNAPTIC PLASTICITY AND COGNITION
BACKGROUND: The group II metabotropic glutamate receptor 3 (mGlu3) is an emerging therapeutic target for schizophrenia, as research has demonstrated a link between mutations in the human gene encoding for mGlu3, GRM3, and clinical diagnosis of schizophrenia. Schizophrenia is known to be accompanied...
Autores principales: | Stansley, Branden, Joffe, Max, Yohn, Samantha, Lindsley, Craig, Niswender, Colleen, Jeffrey Conn, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888595/ http://dx.doi.org/10.1093/schbul/sby016.315 |
Ejemplares similares
-
43.1 GENETIC INSIGHTS LEAD TO DISCOVERY OF SELECTIVE ACTIVATORS OF MGLU1 AND MGLU3 METABOTROPIC GLUTAMATE RECEPTORS AS POTENTIAL TREATMENTS FOR SCHIZOPHRENIA
por: Conn, P Jeffrey, et al.
Publicado: (2018) -
Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders
por: Fisher, Nicole M., et al.
Publicado: (2018) -
T227. THE METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 REGULATES STRIATAL DOPAMINE RELEASE VIA AN ENDOCANNABINOID-DEPENDENT MECHANISM: IMPLICATIONS FOR THE TREATMENT OF SCHIZOPHRENIA
por: Yohn, Samantha, et al.
Publicado: (2018) -
Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function
por: Joffe, Max E., et al.
Publicado: (2017) -
Corrigendum: Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders
por: Fisher, Nicole M., et al.
Publicado: (2018)